March 2017 – The CenterWatch Monthly : PDF
Novo Nordisk, Servier, Otsuka, Teva among top sponsors
Sponsors have done a good job of maintaining, but not improving, the overall quality of their relationships with investigative sites during the past two years, according to a new CenterWatch survey, but performance gaps have widened across several of the attributes sites identify as the most important for conducting a successful study.
Sites wrestle with protocol design complexity
The growing complexity of protocols is resulting in longer cycle times, rising costs and increased pressures on staff and patients throughout the clinical trial process. Tufts Center for the Study of Drug Development (CSDD) studies have found that the number of endpoints, procedures and eligibility criteria of typical phase III protocols increased significantly during 2002-2012, and have continued to grow. These factors combine to increase costs and burdens on research teams.
Also in this issue:
- Top four considerations for sites and sponsors designing immuno-oncology studies
- Facebook offers untapped potential in clinical trial recruitment
- Regulatory Update
- Month in Review
- FDA Actions
- Study Lead Opportunities
- New Drugs in the Pipeline